DMK Pharmaceuticals Corp.

As of July 8, 2024, DMK Pharmaceuticals Corp. is considered overvalued and has moved to a "does not qualify" valuation grade due to a P/E ratio of 0.00, a negative EV to Sales ratio of -1.82, and a 100% decline in stock value over the past year, contrasting sharply with the S&P 500's 17.14% return.

As of August 15, 2016, DMK Pharmaceuticals Corp. is considered overvalued and risky due to its negative P/E ratio, low EV to EBITDA, and negative EV to Sales ratio, despite high ROCE and ROE compared to its peers.

As of April 1, 2025, the market trend is neutral with mixed signals, as weekly indicators show mild bullish momentum while monthly RSI indicates bearishness, leading to uncertainty in the overall outlook.

As of March 2022, the management team of DMK Pharmaceuticals Corp. includes Mr. Richard Williams (Independent Chairman), Dr. Dennis Carlo (CEO), Mr. David Marguglio (Chief Business Officer), Mr. Howard Birndorf (Independent Director), and Ms. Roshawn Blunt (Independent Director). They oversee the company's operations and strategic direction.

As of Jun 18, DMK Pharmaceuticals Corp. has a market capitalization of 0.00, with net sales of 3.62 million and a net profit of -21.15 million over the latest four quarters. As of Dec 22, shareholder's funds are reported at -0.65 million, and total assets amount to 10.93 million.